XYNOMIC PHARMACEUTICALS HOLDINGS, INC. Research and Development Expense
XYNOMIC PHARMACEUTICALS HOLDINGS, INC. reported Research and Development Expense of $12.09 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-06-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2020-06-01
- XYNOMIC PHARMACEUTICALS HOLDINGS, INC. research and development expense for the quarter ending 2019-12-31 was $1.37M, a 92.86% decline year-over-year.
- XYNOMIC PHARMACEUTICALS HOLDINGS, INC. research and development expense for the quarter ending 2019-09-30 was $3.83M, a 127.75% increase year-over-year.
- XYNOMIC PHARMACEUTICALS HOLDINGS, INC. research and development expense for the quarter ending 2019-06-30 was $1.57M, a 59.53% decline year-over-year.
- XYNOMIC PHARMACEUTICALS HOLDINGS, INC. research and development expense for the quarter ending 2018-12-31 was $19.14M.
- XYNOMIC PHARMACEUTICALS HOLDINGS, INC. research and development expense for fiscal 2019 was $12.09M, a 51.94% decline from fiscal 2018.
- XYNOMIC PHARMACEUTICALS HOLDINGS, INC. research and development expense for fiscal 2018 was $25.16M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2019-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-01 | $5.20M derived: sum of 2 quarters · filed 2020-06-01 | $6.77M derived: sum of 3 quarters · filed 2020-06-01 | $12.09M 10-K · filed 2020-06-01 |
| 2019-09-30 | $3.83M 10-Q · filed 2019-11-14 | $5.40M derived: sum of 2 quarters · filed 2019-11-14 | $10.72M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $1.57M 10-Q · filed 2019-08-15 | $6.89M 10-Q · filed 2019-08-15 | ||
| 2018-12-31 | $19.14M derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-01 | $20.82M derived: sum of 2 quarters · filed 2020-06-01 | $24.69M derived: sum of 3 quarters · filed 2020-06-01 | $25.16M 10-K · filed 2020-06-01 |
| 2018-09-30 | $1.68M 10-Q · filed 2019-11-14 | $5.56M derived: sum of 2 quarters · filed 2019-11-14 | $6.02M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $3.87M 10-Q · filed 2019-08-15 | $4.34M 10-Q · filed 2019-08-15 |